These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 9539360)

  • 1. Is levodopa toxic to human substantia nigra?
    Riley D
    Mov Disord; 1998 Mar; 13(2):369-70. PubMed ID: 9539360
    [No Abstract]   [Full Text] [Related]  

  • 2. New use for an old drug: amantadine benefits levodopa-induced dyskinesia.
    Rajput AH; Rajput A; Lang AE; Kumar R; Uitti RJ; Galvez-Jimenez N
    Mov Disord; 1998 Sep; 13(5):851. PubMed ID: 9756161
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements.
    Nutt JG
    Neurology; 2006 May; 66(10):1611-2; author reply 1611-2. PubMed ID: 16717244
    [No Abstract]   [Full Text] [Related]  

  • 4. Hemiparkinsonism and levodopa-induced dyskinesias after focal nigral lesion.
    Růzicka E; Urgosík D; Jech R; Roth J; Vymazal J; Mecír P; Vladyka V
    Mov Disord; 2005 Jun; 20(6):759-62. PubMed ID: 15782419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subchronic administration of L-DOPA to adult rats with a unilateral 6-hydroxydopamine lesion of dopamine neurons results in a sensitization of enhanced GABA release in the substantia nigra, pars reticulata.
    Yamamoto N; Pierce RC; Soghomonian JJ
    Brain Res; 2006 Dec; 1123(1):196-200. PubMed ID: 17027936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements.
    Nyholm D; Jansson R; Willows T; Remahl IN
    Neurology; 2005 Nov; 65(9):1506-7. PubMed ID: 16275852
    [No Abstract]   [Full Text] [Related]  

  • 7. [Freezing phenomenon in Parkinson disease].
    Ringendahl H; Sierla T
    Fortschr Neurol Psychiatr; 1997 Oct; 65(10):435-45. PubMed ID: 9445836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parcopa: a rapidly dissolving formulation of carbidopa/levodopa.
    Med Lett Drugs Ther; 2005 Jan; 47(1201):12. PubMed ID: 15706700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The protective role of levodopa in the human substantia nigra.
    Rajput AH
    Adv Neurol; 2001; 86():327-36. PubMed ID: 11553992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hemiparkinsonism and levodopa-induced dyskinesias following focal nigral lesion.
    Alves R; Barbosa E; Scaff M
    Mov Disord; 2006 Dec; 21(12):2267-8; author reply 2268. PubMed ID: 17078068
    [No Abstract]   [Full Text] [Related]  

  • 11. Polysomnographic and pharmacokinetic findings in levodopa-induced augmentation of restless legs syndrome.
    Vetrugno R; Contin M; Baruzzi A; Provini F; Plazzi G; Montagna P
    Mov Disord; 2006 Feb; 21(2):254-8. PubMed ID: 16200540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pisa syndrome without neuroleptic exposure in a patient with Parkinson's disease: case report.
    Gambarin M; Antonini A; Moretto G; Bovi P; Romito S; Fiaschi A; Tinazzi M
    Mov Disord; 2006 Feb; 21(2):270-3. PubMed ID: 16161148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: a 6-month, randomized, placebo-controlled study.
    Ziegler M; Castro-Caldas A; Del Signore S; Rascol O
    Mov Disord; 2003 Apr; 18(4):418-25. PubMed ID: 12671949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Welcome news about levodopa, but uncertainty remains.
    Fahn S
    Ann Neurol; 1998 May; 43(5):551-4. PubMed ID: 9585348
    [No Abstract]   [Full Text] [Related]  

  • 16. Levodopa in pregnancy.
    Nomoto M; Kaseda S; Iwata S; Osame M; Fukuda T
    Mov Disord; 1997 Mar; 12(2):261. PubMed ID: 9087994
    [No Abstract]   [Full Text] [Related]  

  • 17. Response to L-dopa in PD: the long and the short of it.
    Nutt JG
    Neurology; 2000 May; 54(10):1884-5. PubMed ID: 10822422
    [No Abstract]   [Full Text] [Related]  

  • 18. Normal substantia nigra patients treated with levodopa - Clinical, therapeutic and pathological observations.
    Rajput AH; Rajput ML; Robinson CA; Rajput A
    Parkinsonism Relat Disord; 2015 Oct; 21(10):1232-7. PubMed ID: 26372624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies to modify levodopa treatment.
    Widner H
    Adv Neurol; 2003; 91():229-36. PubMed ID: 12442681
    [No Abstract]   [Full Text] [Related]  

  • 20. Hemiparkinsonism with a discrete lacunar infarction in the contralateral substantia nigra.
    Ohta K; Obara K
    Mov Disord; 2006 Jan; 21(1):124-5. PubMed ID: 16229001
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.